Astria Therapeutics, Inc. (NASDAQ:ATXS) Short Interest Update

Astria Therapeutics, Inc. (NASDAQ:ATXS) saw a significant increase in short interest in November. As of November 30th, there was short interest totalling 3,150,000 shares, an increase of 8.6% from the November 15th total of 2,900,000 shares. Based on an average trading volume of 321,400 shares, the short-interest ratio is currently 9.8 days. Approximately 6.5% of the company’s shares are short sold.

Analyst Upgrades and Downgrades

ATXS has been the topic of a number of recent research reports. Oppenheimer upped their price objective on Astria Therapeutics from $26.00 to $28.00 and gave the company an “outperform” rating in a research report on Thursday, November 14th. HC Wainwright restated a “buy” rating and issued a $16.00 price target on shares of Astria Therapeutics in a research report on Tuesday, December 10th. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $25.60.

Institutional Trading of Astria Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. FMR LLC raised its position in Astria Therapeutics by 29.2% during the 3rd quarter. FMR LLC now owns 7,822,275 shares of the biotechnology company’s stock valued at $86,123,000 after purchasing an additional 1,767,714 shares in the last quarter. Vestal Point Capital LP raised its holdings in shares of Astria Therapeutics by 23.1% in the third quarter. Vestal Point Capital LP now owns 4,000,000 shares of the biotechnology company’s stock valued at $44,040,000 after acquiring an additional 750,000 shares in the last quarter. Nantahala Capital Management LLC bought a new position in Astria Therapeutics during the 2nd quarter worth about $6,142,000. Redmile Group LLC purchased a new position in Astria Therapeutics during the 3rd quarter valued at about $3,423,000. Finally, Cubist Systematic Strategies LLC bought a new stake in shares of Astria Therapeutics in the 2nd quarter valued at about $2,561,000. Institutional investors own 98.98% of the company’s stock.

Astria Therapeutics Stock Performance

ATXS stock traded down $0.08 during midday trading on Tuesday, reaching $9.59. The company’s stock had a trading volume of 4,516 shares, compared to its average volume of 589,777. The firm has a market capitalization of $541.20 million, a price-to-earnings ratio of -4.63 and a beta of 0.67. Astria Therapeutics has a 1 year low of $5.84 and a 1 year high of $16.90. The stock has a fifty day simple moving average of $10.78 and a two-hundred day simple moving average of $10.71.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.